A new COVID-19 vaccine developed at the University of Washington School of Medicine was shown to be safe and effective during a multinational trial of more than 4,000 adults.
A Phase 3 clinical trial found that the second-generation vaccine generates high levels of neutralizing antibodies.
Cryoelectron microscopy studies of Nipah and Hendra viruses may lead to ideas for vaccine design and antibody treatments.
The antibody closely mimics the binding site that the SARS-CoV-2 virus uses to infect cells, and seemingly thwarts invasion via mutation.
Findings could lead to the development of more effective vaccines and antibody treatments for COVID-19 variants.
Molecular research uncovers how these SARS-CoV-2 variants can erode vaccine immunity.
Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern.
Antibodies from recovered patients recognize a lesser-known site on the pandemic coronavirus and block infection in lab studies
Preclinical data published in Cell show the nanoparticle vaccine spurs extremely high levels of protective antibodies in animal models.
The AIDS Clinical Trials Unit at UW Medicine is seeking participants recently infected with the virus.